ʻIke Hou e pili ana i ka lāʻau lapaʻau paʻa

A HOLD Hoʻokuʻu ʻole 2 | eTurboNews | eTN
Avatar o Linda Hohnholz
i kakauia ma Linda Hohnholz

Ua hoʻolaha ʻo Oncolytics Biotech® Inc. i kēia lā i ka hoʻolaha ʻana i ka ʻikepili preclinical e hōʻike ana i ka hana anti-cancer synergistic o ka pelareorep i hui pū ʻia me ka chimeric antigen receptor (CAR) T cell therapy i loko o nā ʻōpū paʻa. ʻO ka pepa, i kapa ʻia ʻo "Oncolytic virus-mediated expansion of dual-specific CAR T cells e hoʻomaikaʻi i ka maikaʻi e kūʻē i nā maʻi maʻi paʻa i nā ʻiole," i paʻi ʻia ma ka Science Translational Medicine me ka hui pū ʻana me nā mea noiʻi ma kekahi mau keʻena hanohano, me ka Mayo Clinic a me Duke University. Hiki ke loaʻa kahi loulou i ka pepa ma ke kaomi ʻana ma aneʻi.

"ʻO ka loaʻa ʻana o kēia mau hopena i paʻi ʻia i loko o kahi puke moʻolelo koʻikoʻi e hāʻawi i ka hōʻoia koʻikoʻi o waho o ko lākou koʻikoʻi," wahi a Thomas Heineman, MD, Ph.D., Luna Lapaʻau Nui o Oncolytics Biotech Inc. ʻO nā lāʻau lapaʻau i nā maʻi maʻi hematologic1, nā immunosuppressive tumor microenvironments (TMEs) o nā maʻi maʻi maʻi paʻa i kaupalena ʻia i ko lākou pono i kēia mau hōʻailona. Ua hōʻike pinepine ʻia ʻo Pelareorep e hoʻohuli i nā TME immunosuppressive, a ma ka paʻi ʻana i kēia manawa ua hōʻike ʻia ka pelareorep e hiki ai i ka pono o nā pūnaewele CAR T i nā kumu hoʻohālike he nui o ka murine solid tumor. He ʻike ikaika kēia, inā i unuhi ʻia i ke keʻena keʻena, hiki ke hoʻomaikaʻi nui i ka wānana o nā maʻi me nā ʻano maʻi maʻi maʻi nui loa ma o ka hāʻawi ʻana i kahi moʻolelo a me kahi koho lapaʻau paʻa. Ma ka hōʻike ʻana i ka hiki ke hoʻomaikaʻi i ka hoʻomanawanui o ka cell T, e hōʻemi i ka pakele antigen, a me ka lanakila ʻana i nā TME paʻa paʻa paʻakikī, ʻo ka hoʻopili ʻana o ka pelareorep e kamaʻilio i nā ala paʻakikī ʻekolu i ka lāʻau lapaʻau CAR T.

Ua hoʻohui ʻo Andrew de Guttadauro, Pelekikena o Oncolytics Biotech US a me Global Head of Business Development, "ʻOiai ke hoʻololi nei i ka mālama ʻana i kekahi mau maʻi maʻi a ʻoi aku ka nui o ka piliona kālā i ke kūʻai ʻana i ka makahiki i hala, ʻo ka CAR T therapies i kēia manawa ke lawelawe wale nei i kahi ʻāpana liʻiliʻi o nā maʻi e loaʻa ana i ka hematologic. ʻinoʻino. Me kēia mau hopena hou loa, ua loaʻa iā mākou nā hōʻike preclinical ikaika e hiki ai i ka pelareorep ke wehe piha i ka waiwai o nā lāʻau lapaʻau CAR T ma o ka hoʻonui ʻana i ko lākou hiki ke kūʻai aku i ka mākeke nui loa o nā maʻi maʻi maʻi e hakakā nei i nā maʻi maʻi koko.

Ua loiloi nā haʻawina preclinical i paʻi ʻia ma ka pepa i ka hoʻomau ʻana a me ka maikaʻi o nā sela CAR T i hoʻokomo ʻia e pelareorep (“CAR/Pela therapy”) i loko o nā kumu hoʻohālike he nui. Ua noiʻi pū ʻia nā hopena o ka hoʻohui ʻana i ka lāʻau lapaʻau CAR/Pela me ka hopena intravenous o pelareorep (“pelareorep boost”). ʻO nā ʻikepili koʻikoʻi a me nā hopena mai ka pepa:

• Ua hoʻomaikaʻi maikaʻi ka hoʻomau a me ka hana anti-cancer o CAR T ke hoʻouka ʻia me ka pelareorep. Ke hoʻohālikelike ʻia i nā lāʻau lapaʻau wale nō, ʻo ka mālama ʻana me CAR/Pela therapy i alakaʻi i nā pōmaikaʻi ola koʻikoʻi i ka ʻili murine a me nā ʻano maʻi maʻi lolo.

• CAR/Pela therapy i ukaliia e ka pelareorep boost i hoonui i ka pono i ka ili murine a me ka lolo ma'i 'a'ai kumu a me ka ma'i ma'i ma'i ma'i ma> 80% o na iole i malamaia ma kela a me keia kŘkohu.

• ʻO ka hoʻouka ʻana i nā pūnaewele CAR T me ka pelareoep i alakaʻi ai i ka hoʻomaikaʻi ʻana i ke kelepona maʻi maʻi ʻaʻai a pale i ka pakele antigen in vivo ma o ka hana ʻana i nā pūnaewele CAR T me nā kikoʻī ʻelua e kuhikuhi ana i kā lākou antigen i hoʻolālā ʻia a me ka antigen cell receptor maoli. Hōʻike kēia mau hualoaʻa e hāʻawi paha ka lāʻau lapaʻau CAR/Pela i nā pono lapaʻau lōʻihi lōʻihi ke hoʻohālikelike ʻia me ka mālama ʻana me nā cell T CAR wale nō.

Ua ʻōlelo ʻo Kauka Matt Coffey, Pelekikena a me Luna Nui o Oncolytics Biotech Inc. a me ka mea kākau pū o ka pepa, "ʻO kēia mau hopena hoihoi he kumu hoʻohālike maikaʻi loa ia o ka hoʻohana ʻana i ka hui pū ʻana me nā alakaʻi manaʻo koʻikoʻi a me nā keʻena noiʻi mua e hoʻonui i ka hiki o ka pelareorep. hopena lapaʻau. ʻAe kēia iā mākou e noʻonoʻo nui i kā mākou papahana maʻi maʻi umauma alakaʻi, ka mea i hōʻike i ke ʻano o ka hiki o pelareorep ke hoʻoikaika i ka hoʻokomo ʻana o ka maʻi T cell e alakaʻi i ka synergy me nā mea hoʻopaneʻe mākaʻikaʻi i loko o ke keʻena. Ke hōʻike nei kēia mau ʻike preclinical hou i nā pono synergistic o pelareorep e hoʻonui aʻe ma mua o nā mea hoʻopaneʻe checkpoint a hōʻike i kahi manawa e hoʻonui ai i kā mākou heluna kanaka maʻi. Ke ʻimi nei mākou i kēia manawa e neʻe nei i mua, manaʻo mākou e hoʻohana i nā pilina me nā mea hoʻonaʻauao a i ʻole nā ​​​​hoa hana ʻoihana i hiki iā mākou ke hoʻomau i ka hoʻokō ʻana i kā mākou mau pahuhopu a me nā ʻoihana me ka maikaʻi.

No ka mea kākau

Avatar o Linda Hohnholz

Linda Hohnholz

Lunahooponopono no eTurboNews ma ka eTN HQ.

kakau
E hoʻomaopopo i
malihini
0 Comments
Nā ʻōlelo Hoʻohui Kūʻai
E nānā i nā ʻōlelo āpau
0
E aloha nui i kou mau manaʻo, e ʻoluʻolu.x
()
x
Kaʻana like i...